Blog

Joanna Shields speaks at the Global Partnership on Artificial Intelligence

At the Global Partnership on Artificial Intelligence (GPAI) summit, Benevolent AI CEO Joanna Shields shared her belief that humanity should be at the heart of AI.

Last week international AI experts across industry, civil society, academia and government from over 60 countries came together virtually for the first plenary of the Global Partnership on Artificial Intelligence (GPAI) in Montreal. At the end of an immensely challenging year, the members reflected on the power AI has to fuel discoveries, empower scientists and shape the world when used responsibly.

Our CEO Joanna Shields, proudly represented the United Kingdom as the newly elected Chair of the Steering Committee and the Multistakeholder Group. She shared the stage with Prime Minister Justin Trudeau and the President of France, Emmanuel Macron, who co-led the effort to establish GPAI through their 2018 and 2019 G7 presidencies. The two world leaders addressed the summit with their vision to guide the responsible development and use of AI globally, with Trudeau describing how ‘we must not forget that positive change doesn’t happen by itself, we have to choose it’.

Joanna opened the final plenary of the day with a speech that echoed these words. She focused on the power human ingenuity and AI has to propel us forward, and ultimately benefit all. She described how AI is at its most powerful when it is the result of a fusion between humanity and technology, as well as the need for purposeful technology which reflects the values of our society.

She drew on her learnings from the first digital revolution and the necessity to ensure that frameworks and standards are embedded in our development of new AI. The purpose of GPAI is to provide these guiding principles because, in her words, ‘AI is a powerful force that we cannot afford to underestimate’.


More Posts

You Might Also Like

News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022